41 results about "Pulmonary embolism" patented technology

The invention relates to the technical field of lung perfusion, in particular to an AI-based lung perfusion evaluation system, which comprises an image quality screening module, a blood vessel positioning analysis module, a blood flow velocity measurement module, a blood vessel anomaly analysis module and an anomaly response module, and is characterized in that the image quality screening module monitors the pixel density of an image and the variation amplitude of color gradient. According to the method, through real-time image definition evaluation and screening, the image selection process is optimized, it is ensured that all the images used for analysis reach the high-quality standard, the gray level change and the edge contour of the blood vessel are automatically calculated, the potential lesion area is accurately positioned and marked, more detailed blood vessel structure analysis is provided, and the accuracy of blood vessel analysis is improved. In addition, the system can rapidly analyze the speed deviation of the blood vessel segment, timely identify the abnormal blood flow, effectively improve the judgment speed of diseases such as pulmonary embolism or pulmonary hypertension, enhance the efficiency of coping with emergency medical conditions through automatic abnormal detection and recording, improve the accuracy and speed of judgment, and support more effective clinical decisions.

A device and method for intravascular treatment of an embolism, and particularly a pulmonary embolism, is disclosed herein. One aspect of the present technology, for example, is directed toward a clot treatment device that includes a support member having a plurality of first clot engagement members and second clot engagement members positioned about the circumference of a distal portion of the support member. In an undeployed state, individual first clot engagement members can be linear and have a first length, and individual second clot engagement members can be linear and have a second length that is less than the first length. The clot engagement members can be configured to penetrate clot material along an arcuate path and hold clot material to the clot treatment device.

The invention relates to the technical field of image processing, and discloses a pulmonary embolism focus segmentation method and system based on image recognition, and a storage medium. The method comprises the following steps: extracting a multi-level blood vessel topological structure of a CTPA image through blood vessel diameter gradient analysis; modeling blood vessel density distribution by using a Weibull mixed model to obtain embolism characteristic parameters; the pixel embolism probability is estimated through variational Bayesian reasoning, and a focus distribution diagram is generated; performing multi-scale feature fusion on the lesion probability graph to obtain a segmentation boundary; and obtaining a final embolism focus segmentation result based on the vascular connectivity constraint optimization boundary. The problems that blood vessel level differentiation processing cannot be achieved, and accurate probability modeling and anatomical constraint verification are lacked are solved. The accuracy of pulmonary embolism focus segmentation is improved.

The invention provides an angiography CT (Computed Tomography) image-based early-stage pulmonary artery micro embolism detection method, which comprises the following steps of: extracting pulmonary parenchyma, and segmenting a small pulmonary blood vessel to obtain a pulmonary blood vessel tree; network weight is updated based on a neural evolution calculation method, and lung arteries and veins are separated; and obtaining a complete pulmonary artery tissue from a pulmonary artery and vein separation result, establishing a level set evolution model to enable the curve to be accurately evolved to the edge of a normal pulmonary artery tissue, and removing the normal pulmonary artery tissue to obtain a pulmonary embolism focus tissue so as to obtain a pulmonary embolism detection result. The method provided by the invention can accurately detect the micro embolism part at the early stage of pulmonary embolism, and has important clinical application value.

The systems and methods of the present invention can remove target material (including blood clots) from body parts (including but not limited to the circulatory system) for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebral vascular embolism, and other vascular obstructions. The capture system may include a tubular body and an end having an opening and a capture guide. In some embodiments, the body or funnel tip of the catheter is expandable.

The present invention provides D-dimer antibodies and their applications and D-dimer detection products, wherein the D-dimer antibodies are selected from protein a and / or protein b, and the amino acid sequences of the heavy chain complementary determining region and the light chain complementary determining region of the antibody are defined. The D-dimer antibodies have good specificity, high biological activity, strong stability, and high affinity with D-dimer, and can be used to prepare products for detecting D-dimer. The D-dimer detection test strips and detection kits provided by the present invention have the advantages of simple operation, rapid response, high sensitivity, strong specificity, suitability for rapid on-site detection, and economical and practical, and can be rapidly screened, and provide auxiliary diagnosis for diseases such as deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation quickly, accurately, and safely, so that patients can be diagnosed and treated early.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The application discloses a method for constructing a 4D FLOW-based hemodynamic evaluation pulmonary embolism prognosis prediction model and application, relates to the medical image technology field, and comprises the following steps: collecting 4D-Flow images of patients who have been diagnosed with pulmonary embolism from medical institutions to obtain image data A; pre-processing the image data A, and dividing the pre-processed image data A into a training set and a verification set according to a proportion; respectively performing imageomic feature extraction, clinical feature extraction and 4D FLOW hemodynamic feature extraction on the training set and the verification set; screening the imageomic features and the clinical features and 4D FLOW hemodynamic detection indexes to obtain key features; and based on the key features, establishing a multi-omics prediction model for pulmonary embolism prognosis prediction, thereby providing a new imaging reference for pulmonary embolism treatment.

A system for treating pulmonary embolism includes an aspiration catheter having a distal occluding component and a holding catheter having a distal valve accessory. In use, expansion of the occluding component blocks a target pulmonary artery, and deployment of the valve accessory promotes mitral valve regurgitation. Suction applied by the aspiration catheter induces a reversal of blood flow throughout a targeted pulmonary region. Reversing the direction of blood flow enables removal of one or more pulmonary emboli.

Methods for performing non-invasive thrombolysis with ultrasound using, in some embodiments, one or more ultrasound transducers to focus or place a high intensity ultrasound beam onto a blood clot (thrombus) or other vascular inclusion or occlusion (e.g., clot in the dialysis graft, deep vein thrombosis, superficial vein thrombosis, arterial embolus, bypass graft thrombosis or embolization, pulmonary embolus) which would be ablated (eroded, mechanically fractionated, liquefied, or dissolved) by ultrasound energy. The process can employ one or more mechanisms, such as of cavitational, sonochemical, mechanical fractionation, or thermal processes depending on the acoustic parameters selected. This general process, including the examples of application set forth herein, is henceforth referred to as “Thrombolysis.”

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

SOLUTION: The present invention relates to a rehabilitation system for lower or upper limbs. A limb rehabilitation system comprises an ankle-assist or wrist-assist rehabilitation device (300) and an intermittent pneumatic compression (IPC) device (305). The limb rehabilitation device (300) which is constituted by a soft elongation actuator assembly (410) is operable so as to minimize joint contracture, while the IPC device (305) is operable so as to increase venous blood flow in a patient at risk and contribute to the prevention of deep vein thrombosis and pulmonary embolism. For lower-limb rehabilitation, the rehabilitation device (300) assists dorsiflexion and plantar flexion, as well as eversion or inversion of the ankle, to improve mobility of the ankle of the user.SELECTED DRAWING: Figure 3B

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The application provides a filter for breaking up thrombus. The filter comprises a power conversion mechanism, a filter support and a cutting mechanism which are connected in sequence along an axial direction and can be radially expanded and contracted; the power conversion mechanism and the cutting mechanism are axially limited and can rotate circumferentially relative to the filter support; the power conversion mechanism can convert the power of blood flow flowing from the cutting mechanism to the power conversion mechanism into rotary motion and can drive the cutting mechanism to rotate circumferentially in the filter support. According to the embodiment of the application, the cutting mechanism is driven by the power conversion mechanism to rotate circumferentially in the filter support, so that the thrombus intercepted in the filter support can be continuously cut and broken up, thereby avoiding pulmonary embolism and preventing blood vessel embolism caused by the filter for breaking up thrombus.

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention relates to the technical field of medical equipment, in particular to a convertible vena cava filter and a combination thereof. The convertible vena cava filter comprises a supporting device, a constraint line and a constraint piece, the restraint line is made of a non-degradable material, and the restraint piece is made of a degradable material so as to restrain the restraint line to form an annular structure; the supporting device comprises a plurality of supporting parts, one end of each supporting part can be limited by a constraint line to form a contraction structure, and the other end of each supporting part forms an expansion structure; and the constraint line is fixedly connected with the supporting part. According to the convertible vena cava filter provided by the invention, the restraint part provides a restraint effect for the restraint line, so that the supporting device is of an umbrella-shaped structure, after the restraint part is degraded and the restraint line loses efficacy, the supporting part is bounced off and is supported on a blood vessel wall, and the restraint line is fixed on the supporting part, so that the problem of pulmonary embolism caused by falling of the restraint line is avoided; the problem that an umbrella-shaped structure and a lantern-shaped structure are difficult to recycle is solved, and the advantages of the umbrella-shaped structure and the barrel-shaped structure are achieved at the same time.

Embodiments of the present specification provide a method for determining a pulmonary embolism index. The method comprises: obtaining a medical image of a subject, the medical image comprising pulmonary blood vessels of the subject, the pulmonary blood vessels of the subject comprising a thrombus; determining information related to the thrombus based on the medical image; dividing the pulmonary blood vessels into at least two hierarchical blood vessels based on the medical image; and determining a pulmonary embolism index of the subject based on the information related to the thrombus and the at least two hierarchical blood vessels.

Mechanisms for indicating estimated pulmonary embolism data are provided, the mechanisms including: receiving medical data; processing the medical data to provide processed data; evaluating the processed data using a first machine learning algorithm using a hardware processor; generating the estimated pulmonary embolism data based on the evaluating the processed data; and causing the expected outcome to be presented to a user. In some of these mechanisms, the medical data is 3D matrix image data from a computed tomography (CT) scan. In some of these embodiments, processing the medical data includes at least one of decompressing, intensity scaling, and resizing the medical data. In some of these mechanisms, the first machine learning algorithm is a deep convolutional neural network.

A lower or an upper limb rehabilitation system is described. The limb rehabilitation system includes assisted-ankle or assisted-wrist rehabilitation device (300) and an intermittent pneumatic compression (IPC) device (305). The limb rehabilitation device (300) is made up of soft extension actuator assemblies (410) that are operable to minimise joint contracture, while the IPC device (305) is operable to increase venous blood flow in at-risk patients to help prevent deep vein thrombosis and pulmonary embolism. For lower limb rehabilitation, the rehabilitation device (300) provides assisted ankle dorsiflexion-plantarflexion and eversion-inversion to improve users' ankle mobility.

The utility model discloses a novel device for preventing lower limb venous thrombosis of a bedridden patient, which comprises a rack assembly, a vibration assembly, a surrounding movement assembly and an inflation assembly, the vibration assembly, the surrounding movement assembly and the inflation assembly are all arranged in the rack assembly, the surrounding movement assembly is arranged above the inflation assembly, and the inflation assembly is arranged above the surrounding movement assembly. A vibration assembly is installed behind the surrounding movement assembly, the lower limbs of a patient are placed in the inflatable foot sleeve, the inflatable foot sleeve conducts intermittent pneumatic repeated compression movement on the lower limbs of the patient through an air pump, the venous blood flow speed of the patient is increased, blood agglutination is prevented, and deep venous thrombosis and pulmonary embolism are prevented. After the patient wears the inflation assembly on the leg, the leg is placed in a positioning soft groove in the surrounding assembly or placed above the vibration assembly, the surrounding movement assembly conducts clockwise rotation movement and anticlockwise rotation movement to simulate back stretching, toe flexion and surrounding movement of the ankle joint of the human body so as to prevent thrombus, and the vibration assembly is used for promoting blood circulation. And thrombus is prevented.

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The invention belongs to the field of disease assessment systems, and particularly relates to a pulmonary artery embolism assessment system. The systematized pulmonary artery embolism evaluation system is constructed by combining the pulmonary artery systolic pressure estimated by tricuspid valve regurgitation and the difference value (Y) of the pulmonary artery systolic pressure estimated by pulmonary artery valve regurgitation pressure, the pulmonary artery blood flow acceleration time, the finger pulse oxygen saturation and other parameters. Compared with a traditional single ultrasonic index (for example, only depending on the increase of pulmonary arterial pressure), the method has the advantages that pulmonary embolism and other diseases (such as left heart related pulmonary hypertension and chronic obstructive pulmonary disease) possibly causing the increase of pulmonary arterial pressure can be effectively distinguished through multi-parameter comprehensive evaluation, so that the accuracy and specificity of pulmonary embolism diagnosis are remarkably improved.

The application relates to the technical field of image processing, and discloses a pulmonary embolism lesion segmentation method and system based on image recognition and a storage medium. The method comprises the following steps: extracting a multi-level blood vessel topological structure of a CTPA image through blood vessel diameter gradient analysis; modeling blood vessel density distribution by using a Weibull mixed model to obtain an embolism characteristic parameter; estimating a pixel embolism probability by using variational Bayesian inference to generate a lesion distribution map; performing multi-scale feature fusion on the lesion probability map to obtain a segmentation boundary; and optimizing the boundary based on blood vessel connectivity constraints to obtain a final embolism lesion segmentation result. The application solves the problems that blood vessel level differentiation processing cannot be realized, accurate probability modeling is lacked, and anatomic constraint verification is lacked. The application improves the precision of pulmonary embolism lesion segmentation.

Systems and methods can remove material of interest, including blood clots, from a body region, including but not limited to the circulatory system for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), cerebrovascular embolism, and other vascular occlusions.

The invention discloses a minimally invasive bone cement device for anterior and posterior thoracolumbar fracture and a using method, and belongs to the technical field of medical equipment, the minimally invasive bone cement device comprises a puncture guide mechanism, a bone cement mechanism and a channel dilator, a shifting piece mechanism is detachably mounted in the channel dilator, and the bottom of a shifting piece body is of an arc-shaped structure; and a bone cement injection mechanism. By arranging the bone cement bag, the leakage risk of the bone cement is solved, the risk that the bone cement leaks to a spinal canal or a para-vertebral tissue is reduced, and therefore serious complications such as nerve injury and pulmonary embolism are avoided. A specific shape can be formed in a fractured vertebral body through the arrangement of the shifting piece mechanism, and uniform distribution of bone cement in the vertebral body is ensured by introducing a bone cement distribution control mechanism, so that the stability of the fractured vertebral body is enhanced, and the treatment effect is improved. And meanwhile, effective recovery of the height of the serious compression fracture centrum is realized, and the physiological curvature and function of the post-operation spine of a patient are improved.

The disclosure relates to treating and preventing coronavirus infections, in particular SARS-CoV-2. The disclosure also relates to treating or preventing cardiovascular symptoms associated with coronavirus infections, including blood clotting, heart attack, stroke, pulmonary embolism and / or thrombosis. The disclosure further relates to antibodies which may be used in such methods.

The present invention relates to the field of lung perfusion technology, and specifically to an AI-based lung perfusion assessment system. The system includes an image quality screening module, a blood vessel positioning analysis module, a blood flow velocity measurement module, a blood vessel abnormality analysis module, and an abnormal response module. The image quality screening module monitors the pixel density and the amplitude of the color gradient change of the image. The present invention optimizes the image selection process through real-time image clarity evaluation and screening, ensuring that all images used for analysis meet high-quality standards, automatically calculates the grayscale changes and edge contours of blood vessels, accurately locates and marks potential lesion areas, and provides more detailed vascular structure analysis. The system can also quickly analyze the velocity deviation of blood vessel segments, promptly identify blood flow abnormalities, and effectively improve the judgment speed of diseases such as pulmonary embolism or pulmonary hypertension. Automated abnormality detection and recording enhances the efficiency of responding to emergency medical situations, improves the accuracy and speed of judgment, and supports more effective clinical decision-making.

The invention discloses a device capable of continuously monitoring and preventing lower limb venous thrombosis and a control method thereof, the device comprises a signal acquisition device, a controller and a host, the signal acquisition device can continuously monitor target venous blood flow dynamics and muscle electric signal changes of human lower limbs, and can electrically stimulate lower limb muscles; the controller can transmit a control instruction sent by the host to the signal acquisition device, and can convert an ultrasonic analog signal and a myoelectricity analog signal into a high-quality ultrasonic image and a specific numerical value of an action potential; the host can send a control instruction to the controller, calculate the blood flow speed and the inner diameter value of a target vein according to the ultrasonic digital signal processed by the controller, monitor and display the blood flow speed and the inner diameter value of the target vein together with the high-quality ultrasonic image and the specific numerical value of the action potential, and select a corresponding electrical stimulation scheme. According to the invention, real-time monitoring and individualized precise prevention of lower limb venous hemodynamics are realized, and powerful support is provided for reducing the incidence rate of clinical lower limb venous thrombosis and pulmonary embolism.

The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction.